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Abstract
Although several randomized clinical trials and observational studies have evaluated the effectiveness, safety and drug sur-
vival of etanercept (ETN) in the treatment of psoriatic arthritis (PsA), long-term data regarding these aspects are currently 
scarce. For this reason, we sought to investigate the long-term survival and safety of ETN in PsA patients in 4 tertiary care 
Spanish hospitals over a 13-year observation period (from 2004 to 2017). The records of 85 PsA patients were reviewed. 
ETN showed an excellent survival profile, with rates of treatment discontinuation at 1, 3, 5 and 10 years of 15, 37, 46 and 
59%, respectively. In our cohort, a trend toward longer drug survival in patients with shorter disease duration and those who 
were treated with ETN as their first biologic agent was observed. On the other hand, combination therapy with conventional 
disease-modifying antirheumatic drugs did not provide greater improvement on the long-term drug survival. Only 12% of 
the patients reported adverse events (AEs) during therapy, being most of them of mild to moderate intensity, and in only 
7% AEs led to drug discontinuation. To the best of our knowledge, the present study shows the largest follow-up period of 
ETN-treated population analyzed in a real-life setting, and these results demonstrate the positive safety profile and long-term 
effectiveness of this biologic agent in the management of PsA patients.
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Introduction
Psoriatic arthritis (PsA) is a chronic and heterogeneous dis-
ease characterized by inflammation of the joints, tendons and 
entheses [1, 2]. Its prevalence among Caucasian population 
is approximately 0.05–0.25%, with an estimated incidence 
ranging from 3.6 to 7.2 per 100,000 person-years [1]. Due to 
pain, swelling and occasional joint deformity, PsA may lead 
to a significant functional impairment and profound impact 
on the patients’ quality of life.
Conventional drug therapy of PsA has mainly consisted 
of non-steroidal anti-inflammatory drugs, regular physi-
otherapy, local injections of corticosteroids, and the con-
ventional synthetic disease-modifying antirheumatic drugs 
(csDMARDs), such as methotrexate (MTX), sulfasalazine 
and leflunomide [2–4]. However, many patients remain 
uncontrolled despite these therapies [3]. The emergence of 
biological tumor necrosis factor-α (TNF-α) inhibitors was a 
breakthrough in the management of PsA, since these agents 
have demonstrated their ability to induce a rapid and per-
sistent clinical remission and improve many aspects of the 
disease [5–7]. As of yet, five TNF-α blockers are licensed for 
PsA management: etanercept (ETN), adalimumab (ADA), 
infliximab (IFX), golimumab and certolizumab, with the 
greater experience and data available on larger cohorts of 
patients for the first three drugs [8].
ETN is a recombinant, dimeric fusion protein consisting 
of two molecules of the soluble, extracellular ligand-binding 
portion of the p75 human TNF receptor linked to the Fc por-
tion of human immunoglobulin  G1 [9]. ETN blocks the inter-
action of TNF with receptors on the cell surface, prevents 
TNF-mediated inflammatory cellular responses and modu-
lates the effects of other TNF-induced molecules [9]. Several 
randomized controlled trials (RCTs) have demonstrated the 
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efficacy and safety of ETN in the treatment of PsA [7, 10]. 
During the past years, additional observational studies have 
also evaluated the effectiveness and drug survival (i.e. the 
length of time a patient continues to take a particular drug) 
of ETN in daily clinical practice [4, 8, 11–13]. However, 
long-term data regarding these aspects are currently scarce.
The primary aim of this study was to evaluate the long-
term drug survival and safety of ETN in patients with PsA 
in a real-life setting over a 13-year observation period. The 
secondary objective was to identify clinical variables that 
could interfere on the long-term drug survival.
Materials and methods
Study design and data collected
This was a retrospective, multicenter, observational study 
that included adult patients who fulfilled the CASPAR 
criteria for PsA [14] consecutively treated with ETN at 4 
tertiary care Spanish hospitals with PsA-specialized units. 
The study comprised the period from June 2004 to Janu-
ary 2017. Patients included failed to respond adequately to 
previous interventions and received ETN therapy according 
to the labelled indications and posology [15] for a mini-
mum of 3 months after appropriate screening tests. The 
Clinical Research Ethics Committee of the centers involved 
granted ethical approval for the study (reference number: 
FGH-ETA-2014-01).
The following data were extracted from the hospital digi-
tal database: demographic data [e.g. age, gender and body 
mass index (BMI)], disease activity at the start of ETN ther-
apy [measured by the disease activity score 28 using c-reac-
tive protein (DAS28-CRP)] disease duration (defined as the 
time from PsA diagnosis to the start of ETN), pattern of 
articular involvement, presence of dactylitis and/or enthesi-
tis, serum levels of c-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) and detection of human leukocyte 
antigen B27 (HLA-B27), prior treatments, presence and 
severity (when appropriate) of cutaneous psoriasis (PsO), 
adverse events (AEs) reported during ETN therapy and 
number of patients who discontinued treatment. Reasons 
for ETN withdrawal were classified as: (i) lack of efficacy; 
(ii) AEs; and (iii) other reasons (moving to another reference 
center, lost to follow-up, etc.). Dermatological and/or rheu-
matological lack of efficacy was mainly determined by the 
clinical judgment of the dermatologists and rheumatologists 
of the specialized units for an inadequate disease control.
Duration of drug survival was calculated as the number 
of months during which individual patients continued their 
treatment with ETN. The start date was the date at which the 
first dose was administered, and the stop date was the date 
of the first missed dose. All observations were censored at 
January 31, 2017. Temporary treatment interruptions (e.g. 
due to infections or surgery) of less than 3 months’ duration 
were allowed.
Statistical analysis
Descriptive statistics were performed for each variable, 
using frequencies and percentages for categorical variables 
and median and range for quantitative variables. Categori-
cal variables were compared between groups using Chi-
squared test, while quantitative variables were compared 
using Mann–Whitney U test. Drug survival was estimated 
according to the Kaplan–Meier survival analysis and further 
analyzed with log-rank statistics. Cox proportional hazard 
models were used to investigate the effect of possible risk 
factors for treatment discontinuation. All analyses were 
made using SPSS version 22.0, and a p value < 0.05 was 
considered statistically significant.
Results
During the observation period, 85 PsA patients received 
treatment with ETN for a minimum of 3 months and, there-
fore, were included in the study. Clinical and demographic 
characteristics of the study population are summarized in 
Table 1. Thirty-nine patients (45.9%) had typical features of 
PsO confirmed either by the rheumatologist or dermatolo-
gist (subjects showing cutaneous lesions without a clearly 
psoriasiform appearance were not labelled as PsO). Fifty-six 
patients (65.9%) had not received previous treatment with 
other biologic agents, 51 (60.0%) received ETN in mono-
therapy and 34 (40.0%) with concomitant csDMARDs 
(MTX in 29 patients and leflunomide in 5). Most patients 
started ETN therapy at a dose of 25 mg administered twice 
weekly or 50 mg once weekly. However, in 12 patients 
(14.1%) an initial induction (50 mg twice weekly) was used 
for up to 12 weeks due to concomitant moderate-to-severe 
PsO. On the other hand, 24 patients (28.2%) optimized ETN 
therapy at a lower dosage rate (e.g. 25 mg once weekly) dur-
ing the follow-up period. Treatment with ETN was associ-
ated with a rapid improvement of the musculoskeletal symp-
toms, showing a significant reduction in the DAS28-CRP 
value at 6 months of treatment [median (range) value of 
DAS28-CRP at baseline and at 6 months: 3.0 (1.4–5.2) and 
1.8 (0.5–4.1), respectively; p < 0.001].
Overall, 10 patients (11.8%) experienced AEs during 
the follow-up period. The most common AEs were local 
reactions at the site of injection (n = 3). Other reported AEs 
included lower respiratory tract infections (n = 2), malignan-
cies (n = 2), development of autoimmune disorders (n = 2) 
(one case of systemic sarcoidosis and one cutaneous lupus 
erythematosus) and uncomplicated headache (n = 1).
Rheumatology International 
1 3
Regarding the status of ETN use throughout the follow-up 
period, 41 patients (48.2%) maintained ETN therapy with a 
median (range) time of 98 months (28–154 months), while 
44 (51.8%) discontinued treatment with a median (range) 
time of 24 months (3–109 months). No significant differ-
ences regarding clinical and demographic features were 
found between these two groups (Table 1). Reasons for ETN 
discontinuation were lack of efficacy in 84.1% of the cases 
(n = 37; in which 31 and 6 cases were due to rheumatological 
and dermatological lack of efficacy, respectively), AEs in 
13.6% [injection site reactions (n = 2), malignancies (n = 2), 
autoimmune disorder (n = 1) and headache (n = 1)] and lost 
to follow-up in 2.3% (n = 1).
Drug survival rates estimated by the Kaplan–Meier analy-
sis are shown in Fig. 1. In our study population, rates of 
treatment discontinuation found at 1, 2 and 3 years were 
15, 27 and 37%, respectively. This positive survival pro-
file was maintained at long-term follow-up, with discon-
tinuation rates at 5, 7.5 and 10 years of 46, 55 and 59%, 
respectively. Regarding the potential predictors of ETN 
withdrawal (Table 2), the previous use of biologic therapies 
was the unique variable related to treatment discontinua-
tion (p = 0.028). A non-significant trend towards longer drug 
survival in patients with shorter disease duration was also 
observed (p = 0.073).
Discussion
Although RCTs are considered the gold standard for assess-
ing efficacy and safety of a specific therapeutic intervention, 
their results are often limited due to their brief follow-up 
Table 1  Clinical and demographic features of PsA patients included in the study
ETN etanercept, BMI body mass index, PsO cutaneous psoriasis, PASI psoriasis area and severity index, PsA psoriatic arthritis, DAS28-CRP 
disease activity score 28 using c-reactive protein, HLA human leukocyte antigen, ESR erythrocyte sedimentation rate, CRP c-reactive protein, 
csDMARDs conventional synthetic disease-modifying antirheumatic drugs
Baseline characteristics All patients (n = 85) Patients who discontin-
ued ETN (n = 44)
Patients who maintained 
ETN (n = 41)
p value
Female sex, n (%) 33 (38.8) 19 (43.2) 14 (34.1) 0.393
Age (years), median (range) 58 (32–89) 57 (34–84) 58.5 (32–89) 0.247
Obesity [BMI (kg/m2) ≥ 30], n (%) 34 (40.0) 19 (43.2) 15 (36.6) 0.535
Concomitant PsO, n (%) 39 (45.9) 17 (38.6) 22 (53.7) 0.165
 Plaque PsO, n (%) 29 (74.4) 11 (64.7) 18 (81.8)
 Inverse PsO, n (%) 3 (7.7) 1 (5.9) 2 (9.1)
 Other variants of PsO, n (%) 7 (17.9) 5 (29.4) 2 (9.1)
PASI (if concomitant PsO), median (range) 13 (2–30) 15 (2–30) 12.8 (2–24) 0.557
Comorbidities
 Diabetes mellitus, n (%) 17 (20.0) 10 (22.7) 7 (17.1) 0.515
 Hyperlipidemia, n (%) 28 (32.9) 14 (31.8) 14 (34.1) 0.819
 Arterial hypertension, n (%) 36 (42.4) 18 (40.9) 18 (43.9) 0.780
Peripheral arthritis, n (%) 74 (87.1) 40 (90.1) 34 (82.9) 0.273
Polyarticular pattern, n (%) 66 (77.6) 31 (70.5) 35 (85.4) 0.099
Axial involvement, n (%) 33 (38.8) 13 (29.5) 20 (48.8) 0.069
Dactylitis and/or enthesitis of heel, n (%) 23 (27.1) 15 (34.1) 8 (19.5) 0.131
PsA activity (DAS28-CRP), median (range) 3.0 (1.4–5.2) 3.1 (1.4–5.2) 2.7 (1.7–5.0) 0.509
Disease duration (months), median (range) 72 (12–468) 96 (12–468) 60 (12–360) 0.055
Positive HLA-B27, n (%) 5 (5.9) 4 (9.1) 1 (2.4) 0.193
ESR serum levels (mm/h), median (range) 15 (2–89) 19 (2–89) 11 (3–56) 0.069
CRP serum levels (mg/dL), median (range) 1.9 (0.1–35.4) 3.6 (0.1–35.4) 1.3 (0.1–30.0) 0.227
Previous treatment with biologic agents, n (%) 29 (34.1) 18 (40.9) 11 (26.8) 0.171
Co-medication with csDMARDs, n (%) 34 (40.0) 19 (43.2) 15 (36.6) 0.535
Adverse events, n (%) 10 (11.8) 8 (18.2) 2 (4.9) 0.057
 Infection, n (%) 2 (20.0) 0 (0) 2 (100)
 Injection site reaction, n (%) 3 (30.0) 3 (37.5) 0 (0)
 Headache, n (%) 1 (10.0) 1 (12.5) 0 (0)
 Malignancy, n (%) 2 (20.0) 2 (25.0) 0 (0)
 Autoimmune disorder, n (%) 2 (20.0) 2 (25.0) 0 (0)
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time and stringent inclusion criteria. Therefore, findings 
based on the real-world evidence including more diverse 
populations and longer follow-up periods are of utmost 
importance. In this regard, during the past years, several 
observational studies have evaluated the drug survival of 
TNF-α blockers in the treatment of PsA in a real-life setting. 
Drug survival is considered a measure of therapeutic success 
as it is largely conditioned by drug efficacy and tolerance. 
Such reports, in overall, reflect the good survival profile of 
these agents in PsA patients, with rates of treatment discon-
tinuation ranging from 12 to 30% at 12 months and from 19 
to 43% at 24 months [4, 8, 12, 13, 16–18]. Similar adherence 
has been shown for ETN therapy in PsA, with discontinua-
tion rates between 14–19, 21–27 and 33–35% at 12, 24 and 
36 months, respectively [12, 13]. In this particular clinical 
setting, ETN seems to exhibit a better drug survival than 
other TNF-α blockers [8, 11, 19]. Although these findings 
support the effectiveness and safety of ETN in PsA in routine 
clinical practice, long-term data, which would provide very 
useful information for the management of PsA, are currently 
scarce. Indeed, to our knowledge, the present study shows 
the largest follow-up period of a ETN-treated population 
analyzed in a real-life setting, with a 13-year observation 
period and a median drug survival of more than 50 months. 
Based on our results, ETN shows persistent long-term effec-
tiveness and limited toxicity. With similar discontinuation 
rates at 1, 2 and 3 years of treatment compared to previous 
reports, this excellent survival profile of ETN was also main-
tained at long-term of follow-up. ETN also showed an excel-
lent long-term safety and tolerability. Thus, in our cohort, 
only 12% of the patients reported AEs during therapy, being 
most of them of mild to moderate intensity, and in only 7% 
AEs led to drug discontinuation.
In patients with chronic inflammatory diseases, TNF-α 
blockers are often administered in combination with csD-
MARDs, particularly MTX, to enhance clinical outcomes, 
reduce risk of immunogenicity and improve drug survival 
[20, 21]. Proposed mechanisms of this phenomenon are the 
synergistic pharmacological effects and the reduction of the 
effect of potential antibodies against the biologic agent [21]. 
Co-medication with MTX or other csDMARDs is also a 
common practice among PsA patients during treatment with 
TNF-α blockers [21]. Although it has been shown that this 
combination therapy does not provide greater improvement 
of PsA clinical symptoms compared to anti-TNF monother-
apy, a more prolonged drug survival may be expected in 
Fig. 1  Drug survival of ETN treatment in PsA shown as the fraction 
(between 1 and 0) of patients remaining on therapy during the obser-
vation period: a in all PsA patients included in the study; b in patients 
with and without prior exposure to biologic agents (p = 0.024), and c 
in patients receiving treatment with ETN in monotherapy or in com-




patients receiving co-medication [4, 17, 19, 21]. However, 
for ETN treatment specifically, some previous reports failed 
to demonstrate this beneficial effect in terms of drug survival 
[20–22], which is consistent with our results. A possible 
explanation for this finding is that the formation of antidrug 
antibodies, which is supposedly one of the main targets of 
csDMARDs co-medication, is rarely detected during ETN 
therapy compared to others TNF-α blockers [23]. Given the 
presumed absence of beneficial effects of the combination 
therapy and the risk of AEs associated with treatment with 
MTX or other csDMARDs, this observation deserves fur-
ther investigations as it might have important implications 
in clinical practice.
Some other clinical variables have been proposed as 
potential predictors of drug discontinuation in PsA patients 
treated with TNF-α blockers. For example, high CRP 
serum levels at baseline have been associated with longer 
drug survival [4, 19], while female gender, older age, or 
higher baseline disease activity has been linked to a pre-
mature drug discontinuation [4, 8, 12, 17, 24]. Although 
such observations could not be corroborated in our study, we 
found that disease duration and the previous use of biologic 
therapies may also have influence on the long-term survival 
of ETN in PsA patients. Thus, a trend toward longer drug 
survival in patients with shorter disease duration and those 
who were treated with ETN as their first biologic agent was 
observed in our cohort. Previous data have also suggested 
that patients receiving their second TNF-α blocker may have 
significantly poorer clinical responses and lower drug sur-
vival compared to patients receiving TNF-α blockers as their 
first biologic agent [25]. These findings, taken together, do 
not imply that ETN should not be attempted in those who 
fail a previous biologic treatment, but should be taken into 
account for a proper patient’s counseling and planning of 
PsA management.
Limitations of this observational study are mainly related 
to its retrospective nature, which may lead to missing or 
incomplete data. The limited number of patients included 
and the non-use of objective scales to evaluate the lack of 
therapeutic efficacy constitute additional limitations. On the 
other hand, the strengths of our study are based on data col-
lection from different centers in a real-life clinical setting 
and the long follow-up period.
In summary, the results from our 13-year experience 
with PsA patients treated with ETN confirm the positive 
safety profile and long-term effectiveness previously shown 
in RCTs and observational studies. In our cohort, a trend 
toward longer drug survival in patients with shorter disease 
duration and those who were treated with ETN as their first 
biologic was observed. On the other hand, concomitant 
csDMARDs might not provide greater improvement on the 
long-term ETN survival in PsA patients. This finding may 
be particularly important in patients with intolerance or con-
traindications to MTX or other csDMARDs.
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